Table 3.
Summary of clinical and molecular characteristics of relapsed patients
| Patient No. | Sex | Age at diagnosis (yr) | INSS stage | MYCN amplification | ALK IHC | ATRX IHC | TERT IHC | Time to relapse (mo) | Outcome/Survival time from relapse (mo) |
|---|---|---|---|---|---|---|---|---|---|
| 4 | M | 3.2 | IV | – | – | No loss | – | 45.1 | AWD, 90.4 |
| 6 | M | 9.8 | III | – | – | No loss | + | 42.5 | DOD, 42.0 |
| 23 | M | 12.2 | IV | – | + | Loss | + | 46.5 | DOD, 55.2 |
| 27 | M | 1.5 | IV | – | + | No loss | – | 83.7 | AWD, 1.0 |
| 28 | M | 7.0 | III | – | – | No loss | + | 11.8 | DOD, 3.7 |
| 31 | M | 7.6 | IV | – | + | No loss | – | 32.8 | DOD, 20.4 |
| 33 | F | 5.3 | IV | NA | + | No loss | – | 21.4 | DOD, 1.9 |
| 37 | F | 0.5 | IV | + | + | No loss | + | 3.4 | DOD, 1.2 |
| 38 | F | 3.6 | IV | – | + | Loss | – | 27.9 | DOD, 55.3 |
| 47 | M | 4.6 | IV | – | + | Loss | + | 25.9 | DOD, 5.6 |
| 50 | M | 2.0 | IV | + | + | No loss | + | 18.8 | DOD, 25.5 |
| 67 | M | 3.3 | IV | – | + | No loss | + | 27.5 | AWD, 17.4 |
| 72 | M | 2.3 | IV | + | + | No loss | – | 9.0 | DOD, 5.8 |
| 75 | F | 1.9 | IV | + | + | No loss | – | 15.6 | DOD, 4.3 |
| 76 | F | 2.7 | IV | – | + | No loss | – | 13.5 | DOD, 1.8 |
| 81 | M | 4.4 | IV | – | + | No loss | + | 13.2 | DOD, 2.2 |
INSS, International Neuroblastoma Staging System; ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; ATRX, alpha thalassemia/mental retardation syndrome X-linked; TERT, telomerase reverse transcriptase; M, male; AWD, alive with disease; DOD, died of disease; F, female; NA, not assessable.